SGEN Seagen

Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union.

Company profile

Clay B. Siegall
Fiscal year end
Former names
IRS number

SGEN stock data



28 Apr 21
17 May 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Seagen earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 373.71M 373.71M 373.71M 373.71M 373.71M 373.71M
Cash burn (monthly) 61.57M (positive/no burn) 40.81M (positive/no burn) 41.78M (positive/no burn)
Cash used (since last report) 96.7M n/a 64.09M n/a 65.61M n/a
Cash remaining 277.01M n/a 309.62M n/a 308.1M n/a
Runway (months of cash) 4.5 n/a 7.6 n/a 7.4 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
11 May 21 Liu Jean I Common Stock Sell Dispose S No Yes 140 1,061 148.54K 64,051
6 May 21 Siegall Clay B Common Stock Sell Dispose S No Yes 134.29 7,723 1.04M 715,209
6 May 21 Siegall Clay B Common Stock Option exercise Aquire M No No 15.46 7,723 119.4K 722,932
6 May 21 Siegall Clay B Common Stock Sell Dispose S No Yes 135.11 18,079 2.44M 715,209
6 May 21 Siegall Clay B Common Stock Option exercise Aquire M No No 15.46 18,079 279.5K 733,288
6 May 21 Siegall Clay B Common Stock Sell Dispose S No Yes 135.75 3,551 482.05K 715,209
6 May 21 Siegall Clay B Common Stock Option exercise Aquire M No No 15.46 3,551 54.9K 718,760
6 May 21 Siegall Clay B NQSO Common Stock Option exercise Dispose M No No 15.46 7,723 119.4K 88,059
6 May 21 Siegall Clay B NQSO Common Stock Option exercise Dispose M No No 15.46 18,079 279.5K 95,782
6 May 21 Siegall Clay B NQSO Common Stock Option exercise Dispose M No No 15.46 3,551 54.9K 113,861

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

3.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1 391 -99.7%
Opened positions 0 49 EXIT
Closed positions 390 144 +170.8%
Increased positions 0 140 EXIT
Reduced positions 1 152 -99.3%
13F shares
Current Prev Q Change
Total value 991.67M 21.05B -95.3%
Total shares 5.66M 105.88M -94.7%
Total puts 0 359.5K EXIT
Total calls 0 631.6K EXIT
Total put/call ratio 0.6
Largest owners
Shares Value Change
Wellington Management 5.66M $991.67M -1.4%
Largest transactions
Shares Bought/sold Change
Capital International Investors 0 -18.64M EXIT
BLK Blackrock 0 -11.68M EXIT
Vanguard 0 -10.88M EXIT
TROW T. Rowe Price 0 -8.94M EXIT
Primecap Management 0 -5.75M EXIT
JPM JPMorgan Chase & Co. 0 -5.05M EXIT
STT State Street 0 -2.94M EXIT
Nuveen Asset Management 0 -2.51M EXIT
FMR 0 -2.25M EXIT
Massachusetts Financial Services 0 -2.04M EXIT

Financial report summary

  • Risks Related to Our Products, Product Candidates and Research and Development
  • Our success depends on our ability to effectively commercialize our products. If we and our collaborators are unable to effectively commercialize our products and to expand their utilization, our ability to generate significant revenue and our prospects for profitability will be adversely affected.
  • Our success also depends on our ability to obtain regulatory approvals for our product candidates and for our current products in additional territories, as well as our ability to expand the labeled indications of use for our current products, and, if the requisite approvals are obtained, our ability to successfully launch and commercialize our products in their approved indications. Our inability to do so could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
  • Reports of adverse events or safety concerns involving our products or product candidates could delay or prevent us from obtaining or maintaining regulatory approvals or could negatively impact sales of our products or the prospects for our product candidates.
  • Clinical trials are expensive and time consuming, may take longer than we expect or may not be completed at all, and their outcome is uncertain.
  • The successful commercialization of our products will depend on a variety of factors, including the extent to which governmental authorities and health insurers establish adequate coverage and reimbursement levels and pricing policies, and the acceptance of our products by the medical community and patients.
  • Our product candidates are in various stages of development, and it is possible that none of our product candidates will ever become commercial products.
  • Any failures or setbacks in our ADC development program or our other platform technologies could negatively affect our business and financial position.
  • We face intense competition and rapid technological change, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.
  • Even if we and our collaborators obtain regulatory approvals to market our current and any future approved products, we and our collaborators will remain subject to extensive ongoing regulatory obligations and oversight, including post-approval requirements, that could result in significant additional expense and could negatively impact our and our collaborators’ ability to commercialize our current and any future approved products.
  • Healthcare law and policy changes may negatively impact our business, including by decreasing the prices that we and our collaborators receive for our products.
  • We are subject to various state, federal and international laws and regulations, including healthcare laws and regulations, that may impact our business and could subject us to significant fines and penalties or other negative consequences.
  • As we continue to expand our operations internationally, we are subject to an increased risk of conducting activities in a manner that violates applicable anti-bribery or anti-corruption laws. We are also subject to laws and regulations covering data privacy and the protection of health-related and other personal information. These laws and regulations could create liability for us or increase our cost of doing business, any of which could have a material adverse effect on our business, results of operations and growth prospects.
  • Enhanced governmental and private scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer donations to patient assistance programs offered by charitable foundations may require us to modify our programs and could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.
  • Product liability and product recalls could harm our business, and we may not be able to obtain adequate insurance to protect us against product liability losses.
  • Our operations involve hazardous materials and are subject to environmental, health and safety controls and regulations.
  • Changes in funding for the FDA, the SEC and other government agencies, or reduced working hours of governmental employees or by the diversion of the efforts and attention of governmental agencies to approval of other therapeutics or other activities related to the COVID-19 pandemic, could prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
  • We depend on collaborative relationships with other companies to assist in the development and commercialization of our products and some of our product candidates and for the development and commercialization of other product candidates utilizing or incorporating our technologies. If we are not able to locate suitable collaborators or if our collaborators do not perform as expected, this may negatively affect our ability to commercialize our products, develop and commercialize our product candidates and/or generate revenues through technology licensing, or may otherwise negatively affect our business.
  • We currently rely on third-party manufacturers and other third parties for production of our drug products and our dependence on these manufacturers may impair the continued development and commercialization of our products and product candidates.
  • To date, we have depended on a small number of collaborators for a substantial portion of our revenue. The loss of any one of these collaborators or changes in their product development or business strategy could result in a material decline in our revenue.
  • We are dependent upon a small number of distributors for a significant portion of our net sales, and the loss of, or significant reduction or cancellation in sales to, any one of these distributors could adversely affect our operations and financial condition.
  • If we are unable to enforce our intellectual property rights or if we fail to sustain and further procure additional intellectual property rights, we may not be able to successfully commercialize our products or any future products and competitors may be able to develop competing therapies.
  • We have been and may in the future be subject to litigation, which could result in substantial damages and may divert management’s time and attention from our business.
  • We and our collaborators rely on license agreements for certain aspects of our products and product candidates and technologies such as our ADC technology. Failure to maintain these license agreements or to secure any required new licenses could prevent us from continuing to develop and commercialize our products and product candidates.
  • We may incur substantial costs and lose important rights or may not be able to continue to commercialize our products or to commercialize any of our product candidates that may be approved for commercial sale as a result of litigation or other proceedings relating to patent and other intellectual property rights, and we may be required to obtain patent and other intellectual property rights from others.
  • The evolving effects of the COVID-19 pandemic and global economic slowdown could have further adverse effects on our business, including our commercialization efforts, supply chain, regulatory activities, clinical development activities and other business operations.
  • If we are unable to manage our growth, our business, financial condition, results of operations and prospects may be adversely affected.
  • Risks associated with our expanding operations in countries outside the U.S. could materially adversely affect our business.
  • We have engaged in, and may in the future engage in, strategic transactions that increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.
  • If we lose our key personnel or are unable to attract and retain additional qualified personnel, our future growth and ability to compete would suffer.
  • If we experience a significant disruption in our information technology systems or breaches of data security, our business could be adversely affected.
  • Our operating results are difficult to predict and may fluctuate. If our operating results are below the expectations of securities analysts or investors, the trading price of our stock could decline.
  • We have a history of net losses. We expect to continue to incur net losses and may not achieve future sustained profitability for some time, if at all.
  • We may need to raise additional capital that may not be available to us.
  • The potential future impairment of intangible assets and goodwill may negatively affect our results of operations and financial position.
  • Our stock price is volatile and our shares may suffer a decline in value.
  • Substantial future sales of shares of our common stock or equity-related securities could cause the market price of our common stock to decline.
  • Our existing stockholders have significant control of our management and affairs.
  • Anti-takeover provisions could make it more difficult for a third party to acquire us.
  • Changes in tax laws or regulations may have a material adverse effect on our business, cash flow, financial condition or results of operations.
  • If any of our facilities are damaged or our clinical, research and development or other business processes are interrupted, our business could be seriously harmed.
  • Increasing use of social media could give rise to liability.
  • Legislative actions and new accounting pronouncements are likely to impact our future financial position or results of operations.
Management Discussion
  • •Achieved 52% growth in net product sales for the quarter ended March 31, 2021 compared to the quarter ended March 31, 2020.
  • •Continued to make strategic investments in our pipeline, commercial launches, infrastructure, and headcount to support our future growth.
  • •Expected publication of the five-year update of the phase 3 ECHELON-1 clinical trial in the second quarter 2021.
Content analysis
H.S. senior Avg
New words: AACR, adjudicated, aggressive, Alliance, analyzing, anesthesiologist, angioimmunoblastic, apparent, ballot, basket, Biden, Brazil, Britain, cemiplimab, cHL, CJEU, clear, climate, conviction, cooperative, cyclophosphamide, departure, differentiation, disaggregated, drawn, EMPOWER, enjoined, epidermal, family, fatal, Great, harbor, hearing, highlighting, Iceland, Importantly, Ireland, Johnson, Lancet, Liechtenstein, malignant, MHRA, modestly, narrowly, Northern, Norway, path, pcALCL, platform, poor, prednisone, procure, protein, rare, referencing, regimen, risky, sBLA, skin, sought, speculative, summary, supplementary, surface, Sutro, topoisomerase, transmit, UK, unpatentable, vaccination, vaccine
Removed: abandoned, added, Affordable, analogy, announcement, assert, assumed, austerity, authorize, automatic, back, banking, BBA, beneficiary, bill, biologic, Bipartisan, Blueprint, borrowing, branded, British, building, bulk, Cadillac, calculate, calculation, calendar, calling, cap, Capitalized, capitalizing, ceiling, certiorari, Circuit, circumvent, claimed, clarified, clarify, Cloud, CMS, Codification, codified, committed, commonly, compare, complicating, concealing, conclusion, Concurrently, conform, Congressional, corporation, dashboard, deducting, deficit, defraud, devise, diagnosed, diffuse, direct, donut, dosed, easier, effecting, elapsed, embezzling, emtansine, encourage, escalating, estate, Euro, executing, exemption, expensed, expiry, explanation, extension, fairly, falsifying, feedback, finalized, fiscal, formal, free, gap, Genitourinary, greatest, heard, Heath, hole, hospital, hosting, hyperglycemia, III, illegal, immune, immunomodulatory, implicit, importance, incorporate, inflating, intentionally, interaction, intervene, intervening, intervention, invalidation, IV, judge, judicial, knowledge, lawful, leverage, literature, lowering, magistrate, maintained, mandate, mature, methodology, moderate, myeloma, negotiated, neuropathy, neutropenia, obstructing, offense, opening, original, outpatient, overcharge, package, partially, passed, passing, paused, penalty, permanently, pharmacy, plaintiff, Pound, PPACA, presentation, President, proceed, programmed, proposal, propose, proteasome, protected, proven, provision, purpose, qualitative, quantitative, qui, reclassification, reclassified, recommend, Reconciliation, recover, relationship, release, released, releasing, Relief, remanded, repeal, repealed, repealing, replace, residual, responded, retaliatory, retreatment, retrospective, revised, ruled, rulemaking, ruling, scheme, scrutinized, Seattle, selected, separation, sequester, shorten, software, solicited, Squibb, stay, stealing, stemming, sufficiently, suit, suspended, Symposium, tam, Taxpayer, tighter, translated, transparent, trend, trillion, unconstitutional, unfit, unit, updating, willfully


Weekly Dosing Regimens for ANTI-CD30 Vc-pab-mmae Antibody Drug-conjugates
13 May 21
Inventors: Eric Sievers, Dana Kennedy
Selective Drug Release from Internalized Conjugates of Biologically Active Compounds
13 May 21
The invention relates to conjugates of biologically active compounds, wherein such a conjugate is comprised of a sequence of amino acids containing a tripeptide that confers selective cleavage by tumor tissue homogenate for release of free drug and/or improves biodistribution into the tumor tissue in comparison to normal tissue homogenate from the same species, wherein the normal tissue is the site of an adverse event associated with administration to a human subject in need thereof of a therapeutically effective amount of a comparator conjugate whose amino acid sequence is a dipeptide known to be selectively cleavable by Cathepsin B.
CD123 Antibodies and Conjugates Thereof
6 May 21
The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD123 and conjugates thereof.
Antibody Drug Conjugates (Adc) That Bind to 158P1D7 Proteins
1 Apr 21
Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer.
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
9 Mar 21
Inventors: Eric Sievers, Dana Kennedy